文献速递MDS 与骨髓增殖性肿瘤白血病

比较2022年更新版WHO和ICC分类下的恶性单核细胞增多症

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
PubMed 文献 · Blood · 2024-01-01

研究以3311例按WHO 2017标准确诊的慢性粒单核细胞白血病(CMML)病例和2130例符合新CMML诊断标准的寡单核细胞增多症病例为基础,比较WHO 2022与ICC 2022分类的影响。WHO 2022新分类的寡单核细胞增多症CMML病例数是ICC的1.5倍,新分类CMML遗传学上富集MDS典型改变,但新分类与已确诊MD-CMML的总生存无差异。

要点

  • WHO 2022新分类的寡单核细胞增多症CMML病例数为ICC的1.5倍,源于诊断标准不同。
  • 新分类CMML病例遗传学富集MDS典型改变,转录亚组与已确诊MD及MP-CMML分离。
  • 新分类与已确诊MD-CMML病例的总生存无差异。

核心结论

  • 尽管细胞遗传学、分子、免疫表型和转录景观不同,新分类与已确诊MD-CMML病例的总生存无差异。
  • 新分类CMML病例处于MDS与先前已确诊CMML之间的疾病连续谱上。

研究设计与样本

  • 研究纳入3311例按WHO 2017标准确诊的CMML病例和2130例符合新CMML诊断标准的寡单核细胞增多症病例。
  • 应用WHO 2022和ICC 2022两套分类系统对病例重新分类。
  • 对新分类CMML病例进行遗传学、细胞遗传学、分子、免疫表型和转录组分析。

主要发现

  • 寡单核细胞增多症病例中新分类为MD-CMML者:WHO 2022为356例,ICC 2022为241例,其中多数按WHO 2017分类诊断为MDS。
  • 按WHO 2022分类为CMML的寡单核细胞增多症病例数是ICC的1.5倍。
  • 新分类CMML病例遗传学分析显示MDS典型改变的强烈富集,形成与已确诊MD和MP-CMML分离的转录亚组。
  • 新分类与已确诊MD-CMML病例的总生存无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The World Health Organization (WHO) classification of hematolymphoid tumors and the International Consensus Classification (ICC) of 2022 introduced major changes to the definition of chronic myelomonocytic leukemia (CMML). To assess its qualitative and quantitative implications for patient care, we started with 3311 established CMML cases (according to WHO 2017 criteria) and included 2130 oligomonocytosis cases fulfilling the new CMML diagnostic criteria. Applying both 2022 classification systems, 356 and 241 of oligomonocytosis cases were newly classified as myelodysplastic (MD)-CMML (WHO and ICC 2022, respectively), most of which were diagnosed as myelodysplastic syndrome (MDS) according to the WHO 2017 classification. Importantly, 1.5 times more oligomonocytosis cases were classified as CMML according to WHO 2022 than based on ICC, because of different diagnostic criteria. Genetic analyses of the newly classified CMML cases showed a distinct mutational profile with strong enrichment of MDS-typical alterations, resulting in a transcriptional subgroup separated from established MD and myeloproliferative CMML. Despite a different cytogenetic, molecular, immunophenotypic, and transcriptional landscape, no differences in overall survival were found between newly classified and established MD-CMML cases. To the best of our knowledge, this study represents the most comprehensive analysis of routine CMML cases to date, both in terms of clinical characterization and transcriptomic analysis, placing newly classified CMML cases on a disease continuum between MDS and previously established CMML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Baumgartner F, Baer C, Bamopoulos S, et al. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022. Blood. 2024. PMID: 38064663. doi:10.1182/blood.2023021199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。